Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Each day that passes, those who are out or shorting fire another shot at their finances. P1a is near an end. No MTD as of yet is never going to be a bad thing. How can not finding major side effects in chemo be branded a negative? Funding? We’ve got it til the end of 2024 or beyond. Will we struggle beyond that? No… we’ve got chemo with extremely tolerable side effects to none at all. We’ve been told we’ll dose closer to standard dox levels but more frequently and for longer. More doses, more often, more revenue for us and with such low side effects, without destroying the lives of patients. It’s a revolution. The market may be incredibly slow to catch on but big pharma aren’t stupid. This disrupts the entire market. Daily SP movements do not matter, look at the likes of Apple as others have pointed out. They catch up in the end. One day that chamber will be full, a red dot will appear and the FUD crew and shorters will be no more.
Ta ta.
Or park it next to the P1a certainly finished H1, partnerships over license deals, and FDA fastrack neither the fastest or best route to go along with fully funded til the end of 2024 at least ramp I came up with…. Oh no wait, that was directly from Avacta. Ooops. Don’t worry, you can buy in Tuesday and join the fun.
Absolutely dreadful publication.
It’s going to be interesting next Thursday when they announce this cohort is already finished……….. (bracing for a rinsing in the EXTREMELY unlikely event it doesn’t) right. I’ll leave that inflammatory post right there. C U Next Tuesday.
The 5th of April. There’s an RNS link right at the top. Click that and all the info is there.
Also at a much higher dose than has ever been given so likely less rounds. The start of the week after as I also said, takes us up to 5 weeks and we could even hit MTD on this cohort. You’ve no idea. The last big gap was a change of protocol. The protocol is now in place. You’re Welcome.
So circa 9 weeks til the end of H1 and the end of P1a. Al seemed very confident. So I believe the back end of next week/start of the next is likely for the end of this cohort and that leaves cohort 6 and 7. We did manage cohort 3 with a much lower dose in circa 6 weeks so it’s all very achievable. I’m guessing they believe they’ll see a marked increase in DLTs in cohort 6 and that confirmed by cohort 7 if it happens. As Avacta stated the reason for finding MTD is commercial for other candidates and to partner/license them out. I believe that’s the reason for no deals yet; they simply don’t quite know what they have. And until they do by finding the limit they can’t put a price on it. IMO. But plenty of news inbound very soon and with the new much improved comms that hopefully spells for lots of updates.
“the recognition that cash is king and a company that is continually going back to the market for more money is going to put a handbrake on investors commitment of buying more stock”
Phew. That’s ok then. We’ve been told just this week that they’re funded right through to the end of 2024, with absolutely tons of news within that period while open to a partnership for pre|CISION. “We can’t possibly bring all of our candidates to market alone”. So that whole point is completely mute. Thanks Wyn.